Age | |
Median, yrs | 64 |
Range, yrs | 6–93 |
Gender, n (%) | |
Female | 359 (55%) |
Male | 298 (45%) |
Stage, n (%) | |
Stage I | 9 (1.4%) |
Stage II | 11 (1.7%) |
Stage III | 54 (8%) |
Stage IV | 506 (77%) |
Unknown | 77 (12%) |
Tumor Type, n (%) | |
Bladder | 4 (0.61%) |
Brain | 15 (2.3%) |
Breast | 34 (5%) |
Cervical | 4 (0.61%) |
Colorectal | 68 (10%) |
Endocrine | 3 (0.46%) |
Endometrial | 25 (3.8%) |
Esophageal | 13 (2%) |
Eye | 1 (0.2%) |
Female Genital | 1 (0.2%) |
Gallbladder | 3 (0.5%) |
Head and Neck | 4 (0.6%) |
Kidney and Renal Pelvis | 10 (1.5%) |
Liver and Bile Duct | 1 (0.15%) |
Lung | 205 (31%) |
Melanoma | 51 (8%) |
Mesothelioma | 4 (0.6%) |
Neuroendocrine Tumors | 14 (2.1%) |
Non-Melanoma Skin | 2 (0.3%) |
Ovarian | 44 (7%) |
Pancreatic | 9 (1.4%) |
Prostate | 34 (5%) |
Sarcoma | 87 (13%) |
Small Intestine | 3 (0.5%) |
Stomach | 3 (0.5%) |
Testicular | 1 (0.2%) |
Thymic | 3 (0.5%) |
Thyroid | 4 (0.6%) |
Unknown Primary | 7 (1%) |
Prior systemic treatment | |
Unknown | 4 (0.6%) |
0 | 156 (24%) |
1+ | 497 (76%) |